Announcements
- Addex to Present at Bio€quity Europe 2024
- Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
- Addex to Present at the Swiss Biotech Day 2024
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
- Addex to Present at the Bio-Europe Spring 2024 Conference
- Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
- Addex to Present at the Swiss Equities Baader Conference
- Addex to Present at Biotech Showcase™ 2024
More ▼
Key statistics
On Thursday, Addex Therapeutics Ltd (ADXN:NAQ) closed at 8.79, 75.70% above the 52 week low of 5.00 set on Dec 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.80 |
---|---|
High | 8.82 |
Low | 8.79 |
Bid | 7.51 |
Offer | 9.04 |
Previous close | 8.82 |
Average volume | 4.60k |
---|---|
Shares outstanding | 1.54m |
Free float | 501.90k |
P/E (TTM) | -- |
Market cap | 14.09m USD |
EPS (TTM) | -209.23 USD |
Data delayed at least 15 minutes, as of May 23 2024 16:21 BST.
More ▼